$PSN

This Equifax Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Equifax (NYSE:EFX), Builders Fir

Analysts upgraded five companies: Baird raised Parsons (PSN) to Outperform with a $57 target; Keybanc upgraded InnovAge (INNV) to Overweight with a $13 target; Rothschild upgraded Equifax (EFX) to Buy with a $235 target; JPMorgan upgraded TIC Solutions (TIC) to Neutral with an $11 target; Morgan Stanley upgraded Ternium (TX) to Overweight with a $65 target.

Original reporting
Published Aug 21, 2026, 2:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 4:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$PSN
Bullish
medium confidence
Mentioned
$PSN · $INNV · $EFX · $TIC · $TX
Relevance
6/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$PSNBullishMed
01

Why it matters

Upgrades generally signal improved expectations and may prompt short-term buying.

02

Market read

Analyst upgrades can drive short-term price moves for the listed companies.

03

What to watch

Potential macro headwinds or sector rotation could offset upgrade benefits.

Relevance 6/10Novelty 6/10Timing: same day

Background

The article aggregates recent analyst rating upgrades across several US-listed companies.

Company-level read

Ticker impact

$PSNBullishMedium confidence
Context

Baird upgraded Parsons Corp to Outperform with a new $57 price target.

Expected impact

moderate upside

Evidence & confidence

Upgrade and higher target may attract buying pressure.

$INNVBullishMedium confidence
Context

Keybanc upgraded InnovAge Holding to Overweight with a $13 price target.

Expected impact

moderate upside

Evidence & confidence

Higher weight and target suggest improved expectations.

$EFXBullishMedium confidence
Context

Rothschild upgraded Equifax to Buy with a $235 price target.

Expected impact

moderate upside

Evidence & confidence

Buy rating and higher target indicate stronger outlook.

$TICNeutralLow confidence
Context

JP Morgan upgraded TIC Solutions to Neutral with a $11 price target.

Expected impact

limited impact

Evidence & confidence

Neutral stance offers little directional bias.

$TXBullishMedium confidence
Context

Morgan Stanley upgraded Ternium to Overweight with a $65 price target.

Expected impact

moderate upside

Evidence & confidence

Overweight rating and higher target suggest better prospects.

Market effects

Analyst upgrades may lift sentiment in the financial services and industrial sectors.

US market may see modest buying in the highlighted stocks.

Limited to US-listed issuers; no broader macro impact.

Counterpoint

Upgrades could be premature if underlying fundamentals remain weak.

Key entities

  • Parsons Corp

    Engineering and construction firm.

  • InnovAge Holding Corp

    Healthcare services provider.

  • Equifax Inc

    Consumer credit reporting agency.

  • TIC Solutions Inc

    Technology services provider.

  • Ternium S.A.

    Steel manufacturing company.

Related articles

$INNVMed

InnovAge Holding Corp. Signals Breakout Year in Earnings

InnovAge Holding Corp. (INNV) reported strong Q4 and fiscal 2026 results, with adjusted EBITDA up 175% YoY to $94.6M. Revenue rose 15.9% to $989.7M, and net income improved significantly. Management expects continued growth in fiscal 2027, with revenue guidance of $1.05B to $1.085B and adjusted EBITDA of $105M to $115M. The company highlighted operational improvements, cost reductions, and strategic investments.

$INNVMedAI 8/10

InnovAge Holding Corp. Q4 2026 Earnings Call Summary

InnovAge Holding Corp. completed 'InnovAge 2.0' in 2026, focusing on operational improvements. 'InnovAge 3.0' will prioritize scaling and expansion. For 2027, the company projects 1.5% to 2.0% net Medicare rate increases and revenue of $1.05B to $1.085B, with growth driven by enrollment and utilization management. Management prefers M&A over de novo centers for capital allocation.